Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Formalizing 'Name And Shame': New Strategy To Rein In Price Increases

Executive Summary

A bipartisan bill would require pharmaceutical manufacturers to provide notice and justification of any price increase over 10%. That formula resonates with Allergan’s recent price pledge, Hillary Clinton’s newest pricing oversight campaign proposal – and may be hard for industry to fend off in the context of must-pass user fee bills in 2017.

Advertisement

Related Content

10 Questions For Bayer's UK CEO On Market Access Reforms In England
Pricing Transparency Policies Not Suited To Generics, GPhA Argues
How Many Pricing Hearings Add Up To Action On Pricing Transparency?
Big Pharma’s Unlikely Price Pledge Leader
The Clinton Drug Price Board, 23 Years Later

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119174

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel